Acurx Pharmaceuticals, Inc. (ACXP) Q2 2026 Earnings: Revenue $0K
ACXP — Q2 2026 Financial Report Analysis
Q2 · Fiscal year 2026 · Published by Pham Hop
Acurx's Q2 2026 net loss held at $2.25M as R&D doubled for a new recurrent C. difficile trial, while a 3.6x rise in share count cut the loss per share to $0.53 and a going-concern warning remains.
Revenue
$0K
Net income
-$2.3M
+0.4% YoY
Diluted EPS
$-0.53
-72.0% YoY
Loss flat, spending shifts to the new trial, and the share count more than triples
Acurx Pharmaceuticals is a clinical-stage drug developer (it has no product on sale and no revenue) working on a new class of antibiotics. Its lead drug, ibezapolstat, targets C. difficile, a gut infection that often comes back after treatment. In the second quarter of 2026 (April–June), Acurx lost $2.25 million, almost exactly what it lost a year earlier ($2.25 million vs $2.25 million). What changed was the mix: research and development (R&D) spending roughly doubled as work began on a new trial in patients whose infection keeps recurring, while overhead fell by about the same amount. The loss per share fell 72%, to $0.53 from $1.89, but that came from the number of shares, not from the business.
At a glance
$10.7 million cash at June 30, up from $7.6 million at the end of 2025. The increase came from selling new shares, not from operations. Management still says this is not enough to fund the company for the next 12 months.
R&D of $1.07 million, up 104%. Per the filing, the increase was $0.3 million of drug-manufacturing costs and $0.3 million of consulting fees for the new recurrent-infection trial. That is the first real ramp in spending on the program this year.
4.26 million average shares vs 1.19 million a year ago. Existing holders' stakes were diluted about 3.6-fold in twelve months. That is why the loss per share shrank while the dollar loss did not.
Key figures
Metric
Q2 2026
Q2 2025
YoY Change
Revenue
$0
$0
n/a (pre-revenue)
Research & development
Read 0 community reports on Acurx Pharmaceuticals, Inc., or write your own.Write a report
$1.07M
$0.52M
+104%
General & administrative
$1.24M
$1.75M
−29%
Total operating expenses
$2.31M
$2.27M
+1.7%
Interest income
$0.05M
$0.02M
+127%
Net loss
−$2.25M
−$2.25M
+0.4% (slightly larger loss)
Loss per share (basic & diluted)
−$0.53
−$1.89
−72.0% (smaller loss per share)
Weighted average shares
4.26M
1.19M
+258%
Cash used in operations (quarter)
$1.71M
$1.67M
+2.4%
Cash at period end
$10.66M
—
vs $7.56M at Dec 31, 2025
Quarterly operating cash use is the six-month figure ($3.12M in 2026, $3.72M in 2025) minus the first-quarter figure from the Q1 10-Q ($1.41M and $2.05M). Operating margin is not meaningful because there is no revenue.
For the first half of 2026, the net loss was $3.94 million, 10% smaller than the $4.40 million a year earlier, mainly because general and administrative costs fell by $0.7 million.
Takeaway: Nothing in this quarter changed the operating loss. The real story is funding: the company doubled its share count in six months, selling stock at an average of $2.68 a share this year versus $9.95 in 2025, and still says its cash won't last a year. Every new dollar for the recurrent-infection program is being raised at lower prices and with more dilution.
Where the money went
R&D (drug development). R&D jumped to $1.07 million from $0.52 million. The filing gives two causes: about $0.3 million more in manufacturing-related costs (making drug supply for the trial) and about $0.3 million more in consulting fees, both "associated with new recurrent CDI trial program." The step-up within 2026 is sharper: first-quarter R&D was only about $0.34 million (six-month $1.41 million minus Q2's $1.07 million), so R&D roughly tripled from Q1 to Q2. This is the spending line that matters for a drug developer, and it has only just started to rise.
General and administrative (overhead). G&A fell to $1.24 million from $1.75 million. The filing attributes this to $0.3 million less in professional fees, $0.1 million less in legal fees and $0.1 million less in share-based compensation (stock and options granted to staff instead of cash, which costs the company no cash but is recorded as an expense). Overhead still exceeded R&D in the quarter: 54% of operating expenses went to G&A and 46% to R&D, up from a 23% R&D share a year earlier.
The clinical plan
In March 2026 Acurx announced it would take ibezapolstat into recurrent C. difficile infection (rCDI). The plan is an open-label pilot trial (patients and doctors know which drug is given) of up to 20 patients who have had at least two recurrences in the past 12 months. Per the 10-Q, start-up work began in the second quarter and first patient enrollment is expected in the fourth quarter of 2026. The pilot's data is meant to shape a later Phase 3 registration trial (the large study needed to apply for approval) against an active comparator. After that, Acurx intends to seek approval under the FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD), a route for drugs aimed at a narrow group of patients with few alternatives.
The case for the drug rests on the completed Phase 2 study. Across both parts of that study, 96% of ibezapolstat patients (25 of 26) were clinically cured by the end of treatment. All 25 of those who were cured stayed free of infection one month later, compared with 12 of 14 (86%) on vancomycin, the standard treatment. These are small patient numbers, and the Phase 2b comparison involved only 32 randomized patients. The company says it intends to partner with a larger drugmaker for late-stage trials and sales rather than run them alone.
What the headline numbers hide
The 72% smaller loss per share is entirely dilution. The net loss was flat, but the weighted average share count rose to 4.26 million from 1.19 million, and shares outstanding went from 2.35 million at December 31 to 4.68 million at June 30. After the quarter ended, another 515,141 shares were sold to Lincoln Park through August 12. The per-share figure improved because the loss was spread across more shares, not because the business improved.
The price of new money has collapsed. Under its equity line with Lincoln Park Capital (an arrangement in which an investor agrees to buy new shares from the company on request, at prices tied to the market), Acurx sold 1.49 million shares in the first half of 2026 at a weighted average of $2.68. In the first half of 2025 it sold at $9.95. The post-quarter sales of 515,141 shares for about $0.7 million work out to roughly $1.36 a share (our division of the filing's figures). The April 2026 direct offering was priced at $3.03 a share and came with warrants for 1.65 million more shares at $2.78, running to May 2028.
Cash use looks slightly better than it is. For the first six months, operating cash outflow ($3.12 million) was $0.8 million smaller than the net loss ($3.94 million). About $0.6 million of that gap is non-cash stock compensation and stock paid to vendors, which is normal. The other $0.4 million came from a rise in unpaid bills: accounts payable and accrued expenses rose 17%, to $2.83 million from $2.42 million. Paying suppliers later holds cash in for now, but it does not reduce what the company spends.
The going-concern warning stands. "Going concern" is the accountants' flag that a company may not be able to keep operating over the next year without new money. The 10-Q says the $10.7 million of cash "will not be sufficient to meet its anticipated cash requirements for at least 12 months" and that this raises "substantial doubt" about the company's ability to continue. At the Q2 cash-use rate of about $1.7 million a quarter, $10.7 million would last about six quarters. We read management's shorter horizon as a sign it expects spending to rise as the rCDI trial and Phase 3 preparation begin. That is our inference: the filing gives no spending forecast.
More dilution is already in place. At June 30 there were 2.57 million warrants outstanding (rights to buy shares at a set price), at a weighted average exercise price of $6.81. That is more than half the shares outstanding. The September 2026 prospectus says up to about $2.8 million more can be drawn from the Lincoln Park line, on top of $9.2 million already received.
No one-offs. There were no impairments, gains or unusual items in either year's quarter. The only income besides expenses was interest on cash ($53,055 vs $23,404), which rose because the cash balance was larger.
Listing risk worth knowing
The 10-Q notes that on July 22, 2026 the SEC approved a new Nasdaq rule requiring every listed company to keep a market value of listed securities of at least $5 million. A company below that level for 30 straight business days would be suspended with no cure period. On July 29 the SEC put the rule on hold pending further review. For a company this small, whether the rule is revived is a live risk. Acurx already did a 1-for-20 reverse stock split in August 2025 to regain compliance with Nasdaq's $1 minimum bid price.
Outlook
Management does not give financial guidance. The milestone it has set is first patient enrolled in the rCDI pilot in Q4 2026. Expect R&D to keep rising from the Q2 level of $1.07 million as that trial starts. We also expect G&A to stay near $1.2–1.3 million a quarter, since most of this year's savings came from lower professional and legal fees.
The more important question is funding. The company has about $10.7 million, around $2.8 million left on the equity line, and a stock price that has recently been low enough that each dollar raised costs more shares. The data that could change that picture, results from a 20-patient pilot, would come after enrollment starts late this year, so it is unlikely before 2027. Until then, the things to watch each quarter are the cash balance, the share count, and whether enrollment starts on schedule. A partnership with a larger drugmaker, which the company says is its plan for late-stage development, is the event that would most change the funding outlook. The filing does not say one is close.
This is the first Acurx report we have published, so there is no earlier outlook to check against.